Skip to main content

Table 7 Efficacy of first-line treatment and non-first line treatment in lenvatinib combination treatment group

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

LEN combination treatment First line treatment (n = 62) Second line treatment (n = 8) Third-line treatment (n = 2) Non-first line treatment (n = 10)
CR 1 0 1 1
PR 19 0 0 0
SD 34 8 0 8
PD 8 0 1 1
ORR 32% 0% 50% 10%
DCR 87% 100% 50% 90%
  1. CR, complete response; DCR, disease control rate; LEN, lenvatinib; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease